Sex and hormonal cycle differences in rat brain levels of pain-related cannabimimetic lipid mediators

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 291, Issue 2, 2006, Pages

  Bradshaw, Heather B ^a   Rimmerman, Neta ^a   Krey, Jocelyn F ^a   Walker, J Michael ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

2 arachidonoyl glycerol; Anandamide; Estrous; N arachidonoyl glycine

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; BUTYRIC ACID DERIVATIVE; DOPAMINE DERIVATIVE; ENDOCANNABINOID; GLYCINE DERIVATIVE; N ARACHIDONOYL DOPAMINE; N ARACHIDONOYL GAMMA AMINO BUTYRIC ACID; N ARACHIDONOYL GLYCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; ESTRUS CYCLE; FEMALE; HIPPOCAMPUS; MALE; MESENCEPHALON; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL; RAT; SEX DIFFERENCE; THALAMUS;

ANIMALS; BRAIN; CANNABINOIDS; CEREBELLUM; CHROMATOGRAPHY, LIQUID; CORPUS STRIATUM; ESTROUS CYCLE; FEMALE; HIPPOCAMPUS; HORMONES; HYPOTHALAMUS; MALE; MASS SPECTROMETRY; MESENCEPHALON; PAIN; PAIN MEASUREMENT; PITUITARY GLAND; RATS; RATS, SPRAGUE-DAWLEY; SEX CHARACTERISTICS; THALAMUS;

EID: 33745849688     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00933.2005     Document Type: Article

References (48)

1. al'Absi M, Wittmers LE, Ellestad D, Nordehn G, Kim SW, Kirschbaum C, and Grant JE. Sex differences in pain and hypothalamic-pituitary-adrenocortical responses to opioid blockade. Psychosom Med 66: 198-206, 2004.
2. Becker JB, Arnold AP, Berkley KJ, Blaustein JD, Eckel LA, Hampson E, Herman JP, Marts S, Sadee W, Steiner M, Taylor J, and Young E. Strategies and methods for research on sex differences in brain and behavior. Endocrinology 146: 1650-1673, 2005.
3. Berkley KJ. Sex differences in pain. Behav Brain Sci 20: 371-380; discussion 435-513, 1997.
4. Bisogno T, Berrendero F, Ambrosino G, Cebeira M, Ramos JA, Fernandez-Ruiz JJ, and Di Marzo V. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem Biophys Res Commun 256: 377-380, 1999.
5. Bradshaw HB and Walker JM. The expanding field of cannabimimetic and related lipid mediators. Br J Pharmacol 144: 459-465, 2005.
6. Craft RM. Sex differences in behavioral effects of cannabinoids. Life Sci 77: 2471-2478, 2005.
7. Devane WA, Dysarz FA, 3rd Johnson MR, Melvin LS, and Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34: 605-613, 1988.
8. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, and Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949, 1992.
9. Edvinsson L and Uddman R. Neurobiology in primary headaches. Brain Res Brain Res Rev 48: 438-456, 2005.
10. Felder CC, Nielsen A, Briley EM, Palkovits M, Priller J, Axelrod J, Nguyen DN, Richardson JM, Riggin RM, Koppel GA, Paul SM, and Becker GW. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett 393: 231-235, 1996.
11. Fride E. Endocannabinoids in the central nervous system: from neuronal networks to behavior. Curr Drug Targets CNS Neurol Disord 4: 633-642, 2005.
12. Geenen R, Jacobs JW, and Bijlsma JW. Evaluation and management of endocrine dysfunction in fibromyalgia. Rheum Dis Clin North Am 28: 389-404, 2002.
13. Gonzalez S, Mauriello-Romanazzi G, Berrendero F, Ramos JA, Franzoni MF, and Fernandez-Ruiz J. Decreased cannabinoid CB1 receptor mRNA levels and immunoreactivity in pituitary hyperplasia induced by prolonged exposure to estrogens. Pituitary 3: 221-226, 2000.
14. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, and Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11: 563-583, 1991.
15. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, Krey JF, Walker JM, Holmes PV, Crystal JD, Duranti A, Tontini A, Mor M, Tarzia G, and Piomelli D. An endocannabinoid mechanism for stress-induced analgesia. Nature 435: 1108-1112, 2005.
16. Huang SM, Bisogno T, Petros TJ, Chang SY, Zavitsanos PA, Zipkin RE, Sivakumar R, Coop A, Maeda DY, De Petrocellis L, Burstein S, Di Marzo V, and Walker JM. Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. J Biol Chem 276: 42639-42644, 2001.
17. Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, Tognetto M, Petros TJ, Krey JF, Chu CJ, Miller JD, Davies SN, Geppetti P, Walker JM, and Di Marzo V. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA 99: 8400-8405, 2002.
18. Kadioglu P, Yalin AS, Tiryakioglu O, Gazioglu N, Oral G, Sanli O, Onem K, and Kadioglu A. Sexual dysfunction in women with hyperprolactinemia: a pilot study report. J Urol 174: 1921-1925, 2005.
19. Kaminski NE, Abood ME, Kessler FK, Martin BR, and Schatz AR. Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol Pharmacol 42: 736-742, 1992.
20. Kempe K, Hsu FF, Bohrer A, and Turk J. Isotope dilution mass spectrometric measurements indicate that arachidonylethanolamide, the proposed endogenous ligand of the cannabinoid receptor, accumulates in rat brain tissue post mortem but is contained at low levels in or is absent from fresh tissue. J Biol Chem 271: 17287-17295, 1996.
21. Laurent P, Becker JA, Valverde O, Ledent C, de Kerchove d'Exaerde A, Schiffmann SN, Maldonado R, Vassart G, and Parmentier M. The prolactin-releasing peptide antagonizes the opioid system through its receptor GPR10. Nat Neurosci 8: 1735-1741, 2005.
22. Martin BR, Compton DR, Thomas BF, Prescott WR, Little PJ, Razdan RK, Johnson MR, Melvin LS, Mechoulam R, and Ward SJ. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav 40: 471-478, 1991.
23. Martinez-Gomez M, Cruz Y, Salas M, Hudson R, and Pacheco P. Assessing pain threshold in the rat: changes with estrus and time of day. Physiol Behav 55: 651-657, 1994.
24. McEwen B. Estrogen actions throughout the brain. Recent Prog Horm Res 57: 357-384, 2002.
25. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, and Pertwee RG, Griffin G, Bayewitch M, Barg J, and Vogel, Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50: 83-90, 1995.
26. Nappi RE, Sances G, Brundu B, De Taddei S, Sommacal A, Ghiotto N, Polatti F, and Nappi G. Estradiol supplementation modulates neuroendocrine response to M-chlorophenylpiperazine in menstrual status migrainosus triggered by oral contraception-free interval. Hum Reprod 20: 3423-3428, 2005.
27. Ong WY and Mackie K. A light and electron microscopic study of the CB1 cannabinoid receptor in the primate spinal cord. J Neurocytol 28: 39-45, 1999.
28. Perez-Rosado A, Manzanares J, Fernandez-Ruiz J, and Ramos JA. Prenatal Delta(9)-tetrahydrocannabinol exposure modifies proenkephalin gene expression in the fetal rat brain: sex-dependent differences. Brain Res Dev Brain Res 120: 77-81, 2000.
29. Piomelli D. The endocannabinoid system: a drug discovery perspective. Curr Opin Investig Drugs 6: 672-679, 2005.
30. Portugal-Santana P, Doretto MC, Tatsuo MA, and Duarte ID. Involvement of prolactin, vasopressin and opioids in post-ictal antinociception induced by electroshock in rats. Brain Res 1003: 1-8, 2004.
31. Randall MD, Kendall DA, and O'Sullivan S. The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol 142: 20-26, 2004.
32. Rodríguez de Fonseca F, Cebeira M, Ramos JA, Martin M, and Fernandez-Ruiz JJ. Cannabinoid receptors in rat brain areas: sexual differences, fluctuations during estrous cycle and changes after gonadectomy and sex steroid replacement. Life Sci 54: 159-170, 1994.
33. Rodriguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, and Navarro M. The endocannabinoid system: physiology and pharmacology. Alcohol 40: 2-14, 2005.
34. Romero EM, Fernandez B, Sagredo O, Gomez N, Uriguen L, Guaza C, De Miguel R, Ramos JA, and Viveros MP. Antinociceptive, behavioural and neuroendocrine effects of CP 55,940 in young rats. Brain Res Dev Brain Res 136: 85-92, 2002.
35. Ross RA. Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol 140: 790-801, 2003.
36. Scorticati C, Mohn C, De Laurentiis A, Vissio P, Fernandez Solari J, Seilicovich A, McCann SM, and Rettori V. The effect of anandamide on prolactin secretion is modulated by estrogen. Proc Natl Acad Sci USA 100: 2134-2139, 2003.
37. Steffens M, Feuerstein TJ, van Velthoven V, Schnierle P, and Knorle R. Quantitative measurement of depolarization-induced anandamide release in human and rat neocortex. Naunyn Schmiedebergs Arch Pharmacol 368: 432-436, 2003.
38. Sugiura T and Waku K. 2-Arachidonoylglycerol and the cannabinoid receptors. Chem Phys Lipids 108: 89-106, 2000.
39. Tseng AH and Craft RM. Sex differences in antinociceptive and motoric effects of cannabinoids. Eur J Pharmacol 430: 41-47, 2001.
40. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, and Walker JM. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83: 393-411, 1998.
41. Valenti M, Vigano D, Casico MG, Rubino T, Steardo L, Parolaro D, and Di Marzo V. Differential diurnal variations of anandamide and 2-arachidonoyl- glycerol levels in rat brain. Cell Mol Life Sci 61: 945-950, 2004.
42. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, Stella N, Makriyannis A, Piomelli D, Davison JS, Marnett LJ, Di Marzo V, Pittman QJ, Patel KD, and Sharkey KA. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310: 329-332, 2005.
43. Vigano D, Rubino T, Vaccani A, Bianchessi S, Marmorato P, Castiglioni C, and Parolaro D. Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems. Psychopharmacology (Berl) 182: 527-536, 2005.
44. Walker JM and Hohmann AG. Cannabinoid mechanisms of pain suppression, In: Cannabinoids, edited by Pertwee RG. New York: Springer, 2005, vol. 168, p. 511-533.
45. Walker JM and Huang SM. Endocannabinoids in pain modulation. Prostaglandins Leukot Essent Fatty Acids 66: 235-242, 2002.
46. Walker JM, Huang SM, Strangman NM, Tsou K, and Sanudo-Pena MC. Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci USA 96: 12198-12203, 1999.
47. Walter L and Stella N. Cannabinoids and neuroinflammation. Br J Pharmacol 141: 775-785, 2004.
48. Woolley CS and McEwen BS. Estradiol mediates fluctuation in hippocampal synapse density during the estrous cycle in the adult rat. J Neurosci 12: 2549-2554, 1992.